Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Item

http://www.wikidata.org/entity/Q33418729

Q33418729

about

Renal Cancer Stem Cells: Characterization and Targeted Therapies NK Cells in HIV Disease The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Adoptive T-Cell Immunotherapy Immunotherapy of Childhood Sarcomas Enhancing Cancer Immunotherapy Via Activation of Innate Immunity Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Adoptive T-cell therapy for cancer: The era of engineered T cells Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Trial Watch-Immunostimulation with cytokines in cancer therapy Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Improving natural killer cell cancer immunotherapy IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Deficiency of Interleukin-15 Confers Resistance to Obesity by Diminishing Inflammation and Enhancing the Thermogenic Function of Adipose Tissues.Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models Common gamma chain cytokines in combinatorial immune strategies against cancer High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Modeling the pharmacokinetic-pharmacodynamic relationship of the monoclonal anti-macaque-IL-15 antibody Hu714MuXHu in cynomolgus monkeys.Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy.IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells Systemic and intratumoral balances between monocytes/macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery.Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).

P2860

Q26746970-F2FC3D28-7912-47DD-B03D-B6D4E45A5017 Q26752833-331B7178-0FCE-4DFA-8591-ADA00DB1EE2C Q26774678-FAA9FEE5-09EE-49DA-BE3E-6B74E59062F3 Q26782845-A0E8CA9B-C3AD-46B8-BAC2-7B21DF022E25 Q26795369-97D19488-3D8E-41F9-AA29-15D2A87436D7 Q26796313-05D1A499-0CC5-4942-BBD5-4D2CCA52B2E9 Q26796316-946404BA-5D5D-4554-930E-6FD851408F82 Q26797345-BBF17718-3B04-4DE9-9B08-943765B44F68 Q26800611-027CCA54-87B8-4997-B900-8FFC6E3B3F43 Q28068375-2404969F-05F8-4ADB-B714-F121C15F1821 Q28068378-85B581F4-B137-4D94-B198-05CB226FC9E4 Q28078725-70FF17AC-93F5-46E2-80C6-B59B11DB2003 Q28079180-28007EDC-0711-4F1E-82D7-096F7BD9F235 Q28087719-D3637950-1FB2-4BC7-A30C-C7BB18587133 Q28088543-4CE3D14C-9106-4C8B-B10C-50700C222B17 Q28088784-44F7AB05-D957-444A-87F1-62CB025B0442 Q30830664-7B0EEFE1-4CF2-42CF-8B80-9B2075A823ED Q33861833-FF4F748E-62D1-4980-B7D5-850AE966B480 Q35600095-33D498C9-FCCB-44D0-B16B-C8B053317326 Q35710332-0FF608C9-7212-41EE-A00D-F9C6B639C073 Q35978264-FDC3C487-28CD-46F1-968E-A900C516775C Q35979037-75E177E6-00A6-4960-A00E-BEAF28F7A427 Q36147727-0E83D442-63DF-4B41-B866-9493707BA548 Q36245682-E6F4BD96-61C8-436A-83B0-E9455305E675 Q36436914-2B71A3A8-B673-4A38-8925-4262652955F1 Q36455872-93318AE9-34BD-4887-8D61-252F1514DC82 Q36517092-C7CD9637-8D5C-4DD2-8B0B-83105EB48A8F Q36539682-9161DF52-B7A1-48DF-AEBF-88A2BCD5717D Q36648845-64A803BB-D094-466C-BD36-2B2675C0D48C Q36884768-882ADC62-79C3-4D32-8691-0F705D871741 Q36980415-F0C732D1-AC02-49BF-9721-74422F15D45B Q37085973-EAEE70E6-5943-4819-B6D5-81387930F5B6 Q37261189-B0DC1F69-9796-4238-9B67-6B739708B50E Q37294760-AD714F62-488F-46CC-AA0A-8650651797E4 Q37327632-31E57A35-0001-4688-ACD6-23EDCE255B46 Q37474007-8F5A946C-B954-484F-949A-04A229DAE2CD Q37580158-1879C150-0A9F-49BE-98D9-C999E05AFADF Q37658381-89F5A98C-F3D3-49D1-8BBA-4FEC65E5A2EE Q37690959-A387F38E-8177-4A76-8FCC-2595DAD4B4BF Q37709365-C052CAA7-4C13-45C1-B17C-A9C3BF4D442B

P2860

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Item

http://www.wikidata.org/entity/Q33418729

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu